Key finding — 80% of participants were biologically confirmed abstinent from smoking at six months — a remarkably high rate compared with conventional cessation therapies, though in a tiny uncontrolled sample.
Study at a glance
| Field | Detail |
|---|---|
| Institution | Johns Hopkins University |
| Design | Open-label pilot study |
| Sample size | 15 participants |
| Intervention | Psilocybin sessions embedded in a cognitive-behavioral smoking-cessation program |
| Year | 2014 |
| Condition | Tobacco addiction |
| Journal | Journal of Psychopharmacology |
| Evidence | speculative |
Limitations
Very small, open-label, no control group, and combined with intensive behavioral therapy — the drug's specific contribution cannot be isolated.
Editorial note
A small but widely discussed pilot suggesting psilocybin might help with smoking cessation. The striking abstinence rate generated enthusiasm, but the uncontrolled design means it remains a promising lead rather than evidence.
Summary written by MMI Editorial for clarity. Always consult the primary source for full methodology and results. The confidence rating reflects our assessment of evidence strength.